The drug is designed to reduce the production of transthyretin, or TTR protein. Curbing TTR limits the accumulation of amyloid deposits in peripheral nerves and various organs that causes them to function abnormally.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/BdaWFDy
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» AstraZeneca, Ionis eye U.S. approval after positive trial data
https://ift.tt/FuRpQ2t
No comments:
Post a Comment